Found­ed by for­mer Phar­mas­set, Idenix ex­ecs, hep B com­pa­ny An­tios nabs $25M Se­ries A

With the scourge of he­pati­tis C un­der con­trol thanks to a slate of large­ly cu­ra­tive treat­ments ap­proved over the last decade, drug de­vel­op­ers have sharp­ened their fo­cus on hep B, which is now con­sid­ered the most com­mon se­ri­ous liv­er in­fec­tion in the world. An­tios Ther­a­peu­tics has joined the pletho­ra of oth­ers in the vi­rol­o­gy space look­ing to make head­way in the fight against the pre­ventable dis­ease, scor­ing $25 mil­lion in an over­sub­scribed Se­ries A round of fund­ing, led by life sci­ences ven­ture cap­i­tal firms Lu­mi­ra Ven­tures and Do­main As­so­ciates.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER